Targeted array CGH

Jun 29, 2012   //   by Peter Rogan   //   array Comparative Genomic Hybridization  //  No Comments
ab initio aCGH

Genomic hybridization with ab initio vs competitor probes

Wouldn’t you want the most reliable data on the market for your clinical studies?

Cytognomix can offer novel array CGH designs with expanded probe sequence repertoire and significantly improved reproducibility than other available platforms. This technology  enables higher density arrays to be produced which provide higher granularity and more consistent copy number calls.  Arrays can be targeted for specific genomic regions to refine results from lower resolution genome-wide studies or developed for genome-wide applications.

A subscription to our  MutationForecaster system provides genome browser access to our genome-wide custom probe designs through the  cytogenetic Visual Analytics Decision Support Tool. This tool displays the locations of oligonucleotide products used in microarray design.

Please contact us regarding these designs and protocols.

We have published a paper describing how ab initio sc technology improves microarray reproducibility: Expanding probe repertoire and improving reproducibility in human genomic hybridizationStephanie N. Dorman; Ben C. Shirley; Joan H. M. Knoll; Peter K. Rogan. Nucleic Acids Research 2013; doi: 10.1093/nar/gkt048

 

 

 

 

 

Targeted aCGH arrays are based on our patented ab initio technology (US Patents 7,734,424,  8,209,129, and 8,407,013).

Comments are closed.